Last reviewed · How we verify
NCT04611373
Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC
Phase 3 trial testing Acetazolamide Levamisole in HCC in 50 participants. Status unknown.
1 December 2020
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 May 2020 |
| Primary completion | 1 December 2020 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Acetazolamide Levamisole — full drug profile →
Conditions studied
- HCC — all drugs for HCC →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Adults 18 to 70, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04611373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HCC
Currently open trials in the same condition.
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
- NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
- NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
- NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611373 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 2 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing